Figitumumab
IGF-1 receptor | |
|---|---|
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6462H9948N1736O2020S54 |
| Molar mass | 146008.04 g·mol−1 |
  (what is this?) (verify) | |
Figitumumab (previously CP-751871) is a
non-small cell lung cancer (NSCLC).[3]
This drug was being developed by Pfizer, but they ceased development of the drug in January 2011 and has stopped its manufacture.[4]
Anti-cancer mechanism
See Insulin-like growth factor 1 receptor role in cancer.
Clinical trials
The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths[5] but others continued.[6][7]
It was to have been included in the I-SPY2 breast cancer trial.[8]
References
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab, American Medical Association.
- PMID 19649631.
- PMID 19632947.
- ^ "Cancer sufferer fears future without 'life-saver' drug". BBC News. July 2014.
- ^ Krauskopf L (29 December 2009). "Pfizer ends late-stage lung-cancer study". Reuters.
- ^ Clinical trial number NCT00976508 for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at ClinicalTrials.gov
- ^ Clinical trial number NCT00635245 for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at ClinicalTrials.gov
- ^ "Breast cancer study aims to speed drugs, cooperation". Reuters. March 2010.